Phase III trial of inhaled interferon beta-1a for treatment of severe COVID-19
The SG018 trial has treated first hospitalised patients with COVID-19 with an inhaled formulation of interferon beta-1a, developed by Synairgen, a UK company. The trial is being conducted in around 20 countries and will enrol 610 COVID-19 patients who require supplemental oxygen.
Source:
PharmaTimes
SPS commentary:
Preliminary data suggest the risk of developing severe disease (requiring ventilation or resulting in death) during the 16-day treatment period was reduced by 79% for patients receiving SNG001 versus placebo. Data also suggest treated patients were more than twice as likely to recover over the course of the treatment period and/or have reduced breathlessness vs placebo.